Delisting risk
Chemomab Therapeutics (ADR) (CMMB)
Develops nebokitug, a CCL24-neutralizing antibody for fibro-inflammatory diseases.
$2.79
Pre-market+0.02 (+0.72%)
At close$2.77(+1.47%)
Something off on this page? Send us feedback.
Next report
Nov 6, 2026
in 64 days
EPS estimate
−$0.01
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$0.14−$0.36−$0.80−$0.24−$0.22−$0.27$0.00Pending
Estimate−$0.20−$0.80−$0.20−$0.20−$0.04−$0.15−$0.04−$0.01
Surprise+30.0%+55.0%−300.0%−20.0%−450.0%−80.0%+92.5%—
RevenueReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.01 | — | — |
| Aug 2026 | −$0.04 | $0.00 | +92.5% |
| Aug 2026 | −$0.15 | −$0.27 | −80.0% |
| May 2026 | −$0.04 | −$0.22 | −450.0% |
| Mar 2026 | −$0.20 | −$0.24 | −20.0% |
The latest year is open to everyone — the 28 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | — | — | — |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | −$0.01 | — | — | — | — | — | — |
| Aug 20, 2026 | −$0.04 | $0.00 | +92.5% | — | — | — | −1.0% |
| Aug 19, 2026 | −$0.15 | −$0.27 | −80.0% | — | — | — | +9.4% |
| May 14, 2026 | −$0.04 | −$0.22 | −450.0% | — | — | — | −2.4% |
| Mar 19, 2026 | −$0.20 | −$0.24 | −20.0% | — | — | — | −7.8% |
The latest year is open to everyone — the 28 quarters behind it read with an account. Sign in | |||||||
| Nov 13, 2025 | |||||||
| Aug 14, 2025 | |||||||
| May 15, 2025 | |||||||
| Mar 3, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Aug 21, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 7, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 14, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 20, 2023 | |||||||
| Nov 11, 2022 | |||||||
| Aug 12, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 9, 2022 | |||||||
| Nov 12, 2021 | |||||||
| Aug 13, 2021 | |||||||
| May 13, 2021 | |||||||
| Mar 9, 2021 | |||||||
| Nov 16, 2020 | |||||||
| Aug 14, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 17, 2020 | |||||||
| Nov 15, 2019 | |||||||
| Aug 5, 2019 | |||||||
| May 22, 2019 | |||||||
| Mar 12, 2019 | — | — | — | — | — | — | — |